Results 121 to 130 of about 92,863 (145)
Some of the next articles are maybe not open access.
Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome
Current Opinion in Lipidology, 2007The goal of identifying subjects with metabolic syndrome is to detect those at higher risk of developing cardiovascular disease. Evidence continues to accumulate as to the superiority of apolipoprotein B and apolipoprotein A-I over the conventional lipoprotein lipids as markers of vascular risk.
Allan D, Sniderman, May, Faraj
openaire +2 more sources
Biochemistry, 2002
Apolipoprotein A-I(Milano) (apoA-I(Milano)) and apoA-I(Paris) are rare cysteine variants of apoA-I that produce a HDL deficiency in the absence of cardiovascular disease in humans. This paradox provides the basis for the hypothesis that the cysteine variants possess a beneficial activity not associated with wild-type apoA-I (apoA-I(WT)). In this study,
John K, Bielicki, Michael N, Oda
openaire +2 more sources
Apolipoprotein A-I(Milano) (apoA-I(Milano)) and apoA-I(Paris) are rare cysteine variants of apoA-I that produce a HDL deficiency in the absence of cardiovascular disease in humans. This paradox provides the basis for the hypothesis that the cysteine variants possess a beneficial activity not associated with wild-type apoA-I (apoA-I(WT)). In this study,
John K, Bielicki, Michael N, Oda
openaire +2 more sources
Apolipoprotein A-I-containing lipoproteins and atherosclerosis
Current Opinion in Lipidology, 1995Apolipoprotein A-I-containing lipoproteins represent a heterogeneous group of lipoparticles. Recent studies suggest that a specific subpopulation within the lipoprotein (AI) subclass may be more effective than other lipoproteins in promoting cholesterol efflux from cells and in the different steps of reverse cholesterol transport. This review describes
A, Leroy +2 more
openaire +2 more sources
Human Gene Therapy, 2000
Elevation of HDL cholesterol, after adenoviral apolipoprotein A-I (apo A-I) gene transfer, may delay or revert ischemic cardiovascular disease, provided transgene expression is persistent. Previously, we observed transient human apo A-I expression after adenoviral gene transfer with a cytomegalovirus (CMV)-driven construct containing the human apo A-I ...
B, De Geest +4 more
openaire +2 more sources
Elevation of HDL cholesterol, after adenoviral apolipoprotein A-I (apo A-I) gene transfer, may delay or revert ischemic cardiovascular disease, provided transgene expression is persistent. Previously, we observed transient human apo A-I expression after adenoviral gene transfer with a cytomegalovirus (CMV)-driven construct containing the human apo A-I ...
B, De Geest +4 more
openaire +2 more sources
Bioscience, Biotechnology, and Biochemistry, 2005
A truncated apolipoprotein (apo) A-I with a molecular weight (M(r)) of 26 kDa was first isolated from the plasma high density lipoproteins of an atypical Japanese eel (Anguilla japonica). Interestingly, this eel contained a very small amount of intact apoA-I (M(r)28 kDa) in the plasma, although serine protease inhibitors were present throughout the ...
Seiichi, Ando +3 more
openaire +2 more sources
A truncated apolipoprotein (apo) A-I with a molecular weight (M(r)) of 26 kDa was first isolated from the plasma high density lipoproteins of an atypical Japanese eel (Anguilla japonica). Interestingly, this eel contained a very small amount of intact apoA-I (M(r)28 kDa) in the plasma, although serine protease inhibitors were present throughout the ...
Seiichi, Ando +3 more
openaire +2 more sources
Human Apolipoprotein A-I Deficiency
2010Our purpose is to review the characteristics of probands described with familial apolipoprotein (apo) A-I deficiency. Decreased plasma high density lipoprotein (HDL) cholesterol levels (
Ernst J. Schaefer, Raul D. Santos
openaire +1 more source
Apolipoprotein A-I: Deficiency in Tangier Disease
1988The near absence of apolipoprotein A-I (apo A-I) characterizes Tangier disease. However, no unequivocal evidence of a molecular defect in apo A-I or apo A-I gene has been established (1-13). It could signify that the molecular defect is not necessarily the same in every patient.
M F, Dumon, M, Clerc, M, Clerc
openaire +2 more sources
Repeated helical pattern in apolipoprotein-A-I
Nature, 1977THE binding of lipids into globules by the serum lipid-binding proteins depends on the unique structures of these proteins. Many have a high α helix content1–4 which is enhanced by the binding of lipid, and their amino acid sequences5–8 suggest that the helices are often ‘amphipathic’ with a long hydrophobic face buried in the lipid surface9,10 and an ...
openaire +2 more sources
The promise of apolipoprotein A-I mimetics
Current Opinion in Endocrinology, Diabetes & Obesity, 2010Synthetic high-density lipoprotein (HDL) and apolipoprotein (apo) A-I mimetic peptides emulate many of the atheroprotective biological functions attributed to HDL and can modify atherosclerotic disease processes. Administration of these agents as HDL replacement or modifying therapy has tremendous potential of providing new treatments for ...
openaire +2 more sources
Human Apolipoprotein A-I Mutants
2010Forty-six mutations in the human APOA1 gene are listed in the Human Gene Mutation Database. Eighteen mutations cause a Low-HDL phenotype associated with an extremely variable atherosclerosis burden and coronary risk, illustrating that the plasma HDL level per se does not necessarily reflect the atheroprotective potential of these lipoproteins, and ...
openaire +1 more source